TITLE:
Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.

CONDITION:
Glioma

INTERVENTION:
131I-TM-601

SUMMARY:

      This drug is being developed to treat a type of brain cancer, glioma. This study was
      designed to determine a safe and well tolerated dose. Patients must have had prior treatment
      for their glioma and be eligible for removal of their recurring tumor.
    

DETAILED DESCRIPTION:

      This is an open label single-dose study to be conducted in 18 evaluable patients with
      recurrent high-grade glioma. Patient will undergone debulking surgery and ventricular access
      device placement into the tumor cavity for administration of 131I-TM-601. High-grade glioma
      includes glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligo-astrocytoma and
      gliosarcoma. The amount of 131I will remain constant. Three doses of TM-601 will be
      administered using a dose escalating scheme.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        -  Patient must have given informed consent

          -  Patient must have histologically confirmed supratentorial malignant glioma

          -  Patients must have recovered from toxicity of prior therapy

          -  Patients must be eligble for resection of the recurrent tumor
      
